1
|
Fantasia F, Di Capua EN, Cenfra N, Pessina G, Mecarocci S, Rago A, Cotroneo E, Busanello A, Equitani F, Lo-Coco F, Nervi C, Cimino G. A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. Ann Hematol 2013; 93:609-16. [PMID: 24173087 PMCID: PMC3945640 DOI: 10.1007/s00277-013-1920-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2013] [Accepted: 10/01/2013] [Indexed: 11/25/2022]
Abstract
In Ph- myeloproliferative neoplasms, the quantification of the JAK2V617F transcripts may provide some advantages over the DNA allele burden determination. We developed a q-RT-PCR to assess the JAK2WT and JAK2V617F mRNA expression in 105 cases (23 donors, 13 secondary polycythemia, 22 polycythemia vera (PV), 38 essential thrombocythemia (ET), and 9 primary myelofibrosis (PMF)). Compared with the standard allele-specific oligonucleotide (ASO)-PCR technique, our assay showed a 100 % concordance rate detecting the JAK2V617F mutation in 22/22 PV (100 %), 29/38 (76.3 %) ET, and 5/9 (55.5 %) PMF cases, respectively. The sensitivity of the assay was 0.01 %. Comparing DNA and RNA samples, we found that the JAK2V617F mutational ratios were significantly higher at the RNA level both in PV (p = 0.005) and ET (p = 0.001) samples. In PV patients, JAK2WT expression levels positively correlated with the platelets (PLTs) (p = 0.003) whereas a trend to negative correlation was observed with the Hb levels (p = 0.051). JAK2V617F-positive cases showed the lowest JAK2WT and ABL1 mRNA expression levels. In all the samples, the expression pattern of beta-glucoronidase (GUSB) was more homogeneous than that of ABL1 or β2 microglobulin (B2M). Using GUSB as normalizator gene, a significant increase of the JAK2V617F mRNA levels was seen in two ET patients at time of progression to PV. In conclusion, the proposed q-RT-PCR is a sensitive and accurate method to quantify the JAK2 mutational status that can also show clinical correlations suggesting the impact of the residual amount of the JAK2WT allele on the Ph- MPN disease phenotype. Our observations also preclude the use of ABL1 as a housekeeping gene for these neoplasms.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Janus Kinase 2/biosynthesis
- Janus Kinase 2/genetics
- K562 Cells
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/diagnosis
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/genetics
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/metabolism
- Male
- Middle Aged
- Myeloproliferative Disorders/diagnosis
- Myeloproliferative Disorders/genetics
- Myeloproliferative Disorders/metabolism
- Real-Time Polymerase Chain Reaction/standards
Collapse
Affiliation(s)
- Francesca Fantasia
- Department of Medico-Surgical Sciences and Biotechnologies, University of Rome “Sapienza” Polo Pontino, , Latina, Italy
| | - Emma Nora Di Capua
- Department of Medico-Surgical Sciences and Biotechnologies, University of Rome “Sapienza” Polo Pontino, , Latina, Italy
| | - Natalia Cenfra
- Department of Cellular Biotechnology and Hematology, University of Rome “Sapienza”–Polo Pontino, via Benevento 6, 00161 Rome, Italy
| | - Gloria Pessina
- Molecular Biology Laboratory, AUSL-VT, Belcolle Hospital, Viterbo, Italy
| | - Sergio Mecarocci
- Hematology unit (2U), S. Maria Goretti Hospital/ICOT, AUSL Latina, Latina, Italy
| | - Angela Rago
- Hematology unit (2U), S. Maria Goretti Hospital/ICOT, AUSL Latina, Latina, Italy
| | - Ettore Cotroneo
- Department of Biomedicine and Prevention, University “Tor Vergata”,, Rome, Italy
| | - Anna Busanello
- Department of Medico-Surgical Sciences and Biotechnologies, University of Rome “Sapienza” Polo Pontino, , Latina, Italy
| | - Francesco Equitani
- Transfusion Medicine and Immuno-Hematology Unit, Santa Maria Goretti Hospital, Latina, Italy
| | - Francesco Lo-Coco
- Department of Biomedicine and Prevention, University “Tor Vergata”,, Rome, Italy
- Laboratory of Neuro-Oncohematology, Santa Lucia Foundation, Rome, Italy
| | - Clara Nervi
- Department of Medico-Surgical Sciences and Biotechnologies, University of Rome “Sapienza” Polo Pontino, , Latina, Italy
| | - Giuseppe Cimino
- Department of Cellular Biotechnology and Hematology, University of Rome “Sapienza”–Polo Pontino, via Benevento 6, 00161 Rome, Italy
- Hematology unit (2U), S. Maria Goretti Hospital/ICOT, AUSL Latina, Latina, Italy
| |
Collapse
|
2
|
Gäbler K, Behrmann I, Haan C. JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT 2013; 2:e25025. [PMID: 24069563 PMCID: PMC3772115 DOI: 10.4161/jkst.25025] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2013] [Revised: 05/13/2013] [Accepted: 05/13/2013] [Indexed: 12/25/2022] Open
Abstract
The Janus kinase 2 (JAK2) mutant V617F and other JAK mutants are found in patients with myeloproliferative neoplasms and leukemias. Due to their involvement in neoplasia and inflammatory disorders, Janus kinases are promising targets for kinase inhibitor therapy. Several small-molecule compounds are evaluated in clinical trials for myelofibrosis, and ruxolitinib (INCB018424, Jakafi®) was the first Janus kinase inhibitor to receive clinical approval. In this review we provide an overview of JAK2V617F signaling and its inhibition by small-molecule kinase inhibitors. In addition, myeloproliferative neoplasms are discussed regarding the role of JAK2V617F and other mutant proteins of possible relevance. We further give an overview about treatment options with special emphasis on possible combination therapies.
Collapse
Affiliation(s)
- Karoline Gäbler
- Signal Transduction Laboratory; Life Sciences Research Unit; University of Luxembourg; Luxembourg
| | - Iris Behrmann
- Signal Transduction Laboratory; Life Sciences Research Unit; University of Luxembourg; Luxembourg
| | - Claude Haan
- Signal Transduction Laboratory; Life Sciences Research Unit; University of Luxembourg; Luxembourg
| |
Collapse
|